Arizona
Tucson; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
California
Los Angeles; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
San Francisco; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Colorado
Colorado Springs; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Denver; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Florida
Boca Raton; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Ocala; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Illinois
Chicago; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Kansas
Kansas City; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Louisiana
New Orleans; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Maryland
Baltimore; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Minnesota
Brunsville; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Minneapolis; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Missouri
Jefferson City; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Kansas City; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
St. Louis; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Nebraska
Omaha; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Nevada
Las Vegas; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
New Mexico
Albuquerque; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Santa Fe; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
New York
Latham; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
New York; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Rochester; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
North Carolina
Cary; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Ohio
Cleveland; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Oklahoma
Oklahoma City; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Tulsa; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Oregon
Portland; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Pennsylvania
Philadelphia; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
South Carolina
Greenville; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Texas
Austin; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Dallas; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Ft. Worth; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
San Antonio; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Tyler; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Utah
Salt Lake City; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Virginia
Richmond; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
Washington
Spokane; Research Site
A study for adults with refractory chronic ITP (Immune Thrombocytopenic Purpura) evaluating the safety and efficacy of SB-497115, an oral thrombopoietin receptor agonist.
